Tampaki, Maria;
Tsochatzis, Emmanouil;
Lekakis, Vasileios;
Cholongitas, Evangelos;
(2025)
Prevalence, characteristics and outcomes of patients with metabolic and alcohol related/associated liver disease (MetALD): a systematic review and meta-analysis.
Metabolism
, 163
, Article 156101. 10.1016/j.metabol.2024.156101.
![[thumbnail of Tsochatzis_R2 MetALD send.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Tsochatzis_R2 MetALD send.pdf Access restricted to UCL open access staff until 13 December 2025. Download (337kB) |
Abstract
Background: In light of the new nomenclature of steatotic liver disease (SLD), we aimed to enhance the existing knowledge on the epidemiology and clinical outcomes of metabolic and alcohol related/associated liver disease (MetALD). Methods: A systematic review and meta-analysis were performed in Medline/PubMed, Embase, Scopus and Cochrane databases to evaluate the prevalence and outcomes of MetALD within the SLD population and to compare the characteristics between MetALD patients and those with metabolic dysfunction associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD). Nineteen studies from nine countries that evaluated 4,543,341 adult participants with SLD were included. Results: The pooled overall prevalence of MetALD among the SLD population was 10 % (95%CI:7–13 %) without significant difference between Asian and non-Asian populations. However, MetALD was more frequent in men than women (86 % vs 14 %, p < 0.01), while Asian MetALD patients, were more frequent men (92 % vs 66 %, p < 0.01) compared to non-Asians. Additionally, in terms of metabolic characteristics there were no significant differences between MetALD, MASLD and ALD patients. Regarding outcomes, patients with MetALD, compared to non-SLD, were at increased risk of all-cause [HR 1.44 (95%CI:1.24–1.66)], cardiovascular disease (CVD) [HR 1.17 (95%CI:1.12–1.21)] and cancer-related mortality [HR 2.07 (95%CI:1.32–3.25)]. Finally, patients with MetALD, had increased incidence of CVD and liver decompensating events, compared to non-SLD participants [HR 1.49 (95%CI:1.03–2.15); HR 10.55 (95%CI:3.46–32.16) respectively]. Conclusions: Based on the existing literature, patients with MetALD consist a significant part of the SLD population, with high all-cause, CVD and cancer-related mortality and increased risk for CVD and hepatic decompensation.
| Type: | Article |
|---|---|
| Title: | Prevalence, characteristics and outcomes of patients with metabolic and alcohol related/associated liver disease (MetALD): a systematic review and meta-analysis |
| Location: | United States |
| DOI: | 10.1016/j.metabol.2024.156101 |
| Publisher version: | https://doi.org/10.1016/j.metabol.2024.156101 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Endocrinology & Metabolism, MetALD, Metabolic dysfunction associated steatotic liver, disease, Alcohol related liver disease, Steatotic liver disease, SLD, MASLD, ALD, ALL-CAUSE MORTALITY, CARDIOVASCULAR EVENTS, PUBLICATION BIAS, CONSUMPTION, RISK, IMPACTS |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inst for Liver and Digestive Hlth |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10204528 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
